CNS Drugs

From Proof of Principle to Therapeutic Discipline: Strategies to Improve the Benefit/Risk Profile of Amyloid-Targeting Treatments for Alzheimer's Disease

By Robert Perneczky, Frank Jessen, Timo Grimmer, Anna Hofmann

ReviewInterventions

The paper

Robert Perneczky, Frank Jessen, Timo Grimmer, Anna Hofmann

German Center for Neurodegenerative Diseases; Washington University in St. Louis

CNS Drugs, 15 Sep 2026

doi.org/10.1007/s40263-026-01333-5 PubMed 42742914

Research Square4 Oct 2026
Brain diffusivity modifies plasma pTau217 links to pathology
Annals of Neurology4 Oct 2026
Plasma pTau217 and recall test refine prognosis in Down syndrome
Neurology4 Oct 2026
Plasma p-tau217 yields discordant Alzheimer results in 8.5% of adults
medRxiv5 Oct 2026
Blood eMTBR-tau linked to Alzheimer’s tangles at autopsy